• By ICR Secretariat
  • Posted Monday, August 5, 2019

Amgen's KRAS drug shows promise in 2 additional cancers: colorectal and appendiceal

https://www.fiercebiotech.com/biotech/amgen-s-kras-drug-hits-mark-2-additional-cancers-colorectal-and-appendiceal

Amgen’s KRAS inhibitor made a splash at this year’s American Society of Clinical Oncology (ASCO) annual meeting, and with good reason—it was the first drug of its class to post clinical data.